- Home
- Publications
- Publication Search
- Publication Details
Title
Expression of the immune checkpoint VISTA in breast cancer
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-04-07
DOI
10.1007/s00262-020-02554-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
- (2019) Jorge Blando et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma
- (2019) Heike Loeser et al. OncoImmunology
- Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
- (2019) Jarem Edwards et al. CLINICAL CANCER RESEARCH
- PD ‐L1, B7‐H3 and VISTA are highly expressed in gestational trophoblastic neoplasia
- (2019) Liju Zong et al. HISTOPATHOLOGY
- HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor
- (2019) Yuanyuan Liu et al. BREAST CANCER RESEARCH AND TREATMENT
- VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer
- (2019) Liju Zong et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- VISTA is an acidic pH-selective ligand for PSGL-1
- (2019) Robert J. Johnston et al. NATURE
- VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma
- (2018) Ming Zhang et al. BMC CANCER
- VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival
- (2018) Lawrence F. Kuklinski et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets
- (2018) Ádám Nagy et al. Scientific Reports
- VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
- (2018) Liru Wang et al. OncoImmunology
- Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors
- (2018) Shan Xie et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- VSIG-3 as a ligand of VISTA inhibits human T cell function
- (2018) Jinghua Wang et al. IMMUNOLOGY
- TIM-3 expression in breast cancer
- (2018) Samantha Burugu et al. OncoImmunology
- VISTA expressed in tumour cells regulates T cell function
- (2018) Kumuluzi Mulati et al. BRITISH JOURNAL OF CANCER
- Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing
- (2018) Zihai Li et al. Journal of Hematology & Oncology
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
- (2017) Hojabr Kakavand et al. MODERN PATHOLOGY
- Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer
- (2017) Thomas A Adams et al. MODERN PATHOLOGY
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- (2017) Jianjun Gao et al. NATURE MEDICINE
- The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
- (2017) Christine Böger et al. OncoImmunology
- HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline
- (2016) Yao-Shan Fan et al. BREAST CANCER RESEARCH AND TREATMENT
- c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer
- (2016) Xinyu Ren et al. TUMOR BIOLOGY
- Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes
- (2016) Sasha E. Stanton et al. JAMA Oncology
- A New VISTA on combination therapy for negative checkpoint regulator blockade
- (2016) Jie Deng et al. Journal for ImmunoTherapy of Cancer
- Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
- (2015) Jun Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
- (2015) Tao Qin et al. Oncotarget
- Prognostic and predictive value of PDL1 expression in breast cancer
- (2015) Renaud Sabatier et al. Oncotarget
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
- (2012) Douglas G. Altman et al. PLOS MEDICINE
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
- (2011) Li Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started